Loading clinical trials...
Loading clinical trials...
A Multicentre, Randomized, Double-blind, Phase III Study of The Comparative Immunogenicity, Safety and Tolerability of Two Japanese Encephalitis Vaccines (ChimeriVax™-JE and JE-VAX®)
The purpose of this study is to determine non-inferiority in seroconversion and to compare the safety and tolerability between ChimeriVaxTM-JE and JE-VAX to the respective homologous virus strain after completion of vaccination course.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Chicago, Illinois, United States
Shawnee Mission, Kansas, United States
Missoula, Montana, United States
Dallas, Texas, United States
Tacoma, Washington, United States
Adelaide, Australia
Melbourne, Australia
New South Wales, Australia
Queensland, Australia
Victoria, Australia
Start Date
November 1, 2005
Primary Completion Date
June 1, 2006
Completion Date
November 1, 2006
Last Updated
December 6, 2012
820
ACTUAL participants
ChimeriVax™-JE
BIOLOGICAL
JE-VAX®
BIOLOGICAL
Lead Sponsor
Sanofi
NCT06372665
NCT00594958
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT04817917